Perioperative Management of Colorectal Cancer Patients Infected With COVID-19: a Multicenter Prospective Cohort Study.

Changhai Hospital300 enrolled

Overview

This trial is a multicenter prospective cohort study to explore timing of colorectal cancer surgery after COVID-19 infection so that can assist clinicians and patients. Currently, there is less evidence on perioperative outcomes after COVID-19 vaccination and the omicron variant. Therefore, it is necessary to update previously published consensus which recommends that patients should avoid elective surgery within 7 weeks of COVID-19 infection remain, unless the benefits of doing so exceed the risk of waiting. Aiming at the above problems, we plan to carry out a multicenter prospective cohort study to develop perioperative management according patients' different conditions.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Colorectal Cancer Surgical Procedure, Unspecified

Interventions

Timing of colorectal cancer surgeryPROCEDURE

The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * undergoing colorectal cancer surgery * infected with COVID-19 but nucleic acid test result is negative * the patients compliance is good * signed the consents voluntarily Exclusion Criteria: * undergoing emergency surgery(intestinal obstruction, intestinal perforation, intestinal hemorrhage, et al.) * The patients' situations which judged by situations is not suitable to participate in the clinical trial

Outcomes

Primary Outcomes

Incidence of surgical complications

Complications including: intraperitoneal hemorrhage, anastomotic leak, anastomotic bleeding, abdominal infection, pulmonary infection, chylous fistula, intestinal obstruction, et al.

Time frame: 30 days after surgery